...Cypress acquired Cellatope's cell-bound complement activation products (CB-CAP) technology for $2 million in cash and $3...
...expects to launch the test in mid-2010. Cypress markets Avise pharmacogenetics tests for rheumatoid arthritis. Cellatope...